Discontinued — last reported Q1 '26
EBIT at other companies
Other financials
Where this comes from
Calculated from MoonLake Immunotherapeutics’s reported figures.
Plus components not separately reported this period.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's EBIT?
- MoonLake Immunotherapeutics (MLTX) reported EBIT of -$70.02M in Q1 2026.
- How has MoonLake Immunotherapeutics's EBIT changed year-over-year?
- MoonLake Immunotherapeutics's EBIT decreased by 47.5% year-over-year, from -$47.49M to -$70.02M.
- What is the long-term trend for MoonLake Immunotherapeutics's EBIT?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's EBIT has grown at a 170.5% compound annual growth rate (CAGR), from -$4.57M to -$244.84M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.